Bradley J . Monk, MD
Professor
Contact
School of Medicine
Obstetrics and Gynecology Residency
Arizona Health
Bradley J . Monk, MD
Professor
Department
Obstetrics & Gynecology (Phoenix)
Position
Professor
Publications
- Oncology and therapy
Monk Bradley J., Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States 2024 - Gynecologic oncology
Hunsberger Kyra, Standard of care treatment for stage IVB cervical cancer: A systematic review and meta-analysis
190, p. S421 - S421 2024 - Gynecologic oncology
Konstantinopoulos Panagiotis, Efficacy and safety of alpelisib plus olaparib versus chemotherapy among patients with platinum-resistant or refractory high-grade serous ovarian cancer without BRCA mutation: Primary analysis of the EPIK-O trial
190, p. S12 - S12 2024 - Annals of oncology
Lorusso D, Pembrolizumab Plus Chemotherapy for Advanced and Recurrent Cervical Cancer: Final Analysis According to Bevacizumab Use in the Randomized KEYNOTE-826 Study 2024 - International journal of gynecological cancer
Grisham Rachel, GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer, p. ijgc-2024-005919 2024 - European journal of cancer (1990)
Nakamura Y., 3 Oral: Tucatinib and Trastuzumab for Patients With Previously Treated, HER2- Altered Solid Tumors (SGNTUC-019): A Phase 2 Basket Study
211, p. 114532 2024 - Gynecologic oncology
Monk Bradley J., Should we consider progression-free survival benefits enough for drug approvals in locally advanced cervical cancer?
189, p. 146 - 147 2024 - International journal of gynecological cancer
Valabrega Giorgio, Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the E, p. ijgc-2024-005484 2024 - Annals of oncology
Monk B.J., Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial 2024 - Cancer medicine (Malden, MA)
Hasegawa Kosei, Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer
13:18, p. e70236 2024 - Future oncology (London, England)
Nemunaitis John, Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy, p. 1 - 16 2024 - Annals of oncology
Powell M. A., Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel- paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial
35:8, p. 728 - 738 2024 - Future oncology (London, England)
Mirza Mansoor R, A Plain Language Summary of 'Dostarlimab for primary advanced or recurrent endometrial cancer', p. 1 2024 - International journal of gynecological cancer
Graybill Whitney S, Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study
34:7, p. 1041 - 1050 2024 - International journal of gynecological cancer
Salani Ritu, A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04), p. ijgc-2024-005588 2024 - Journal of clinical oncology
Lee Yeh Chen, Racial disparities and survival outcome of patients with locally advanced cervix cancer in the international randomised phase 3 OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274)
42:16_suppl, p. 1594 - 1594 2024 - Journal of clinical oncology
Lokich Elizabeth, Time course of adverse events in primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN-6-NSGO/GOG-3031/RUBY trial
42:16_suppl, p. 5607 - 5607 2024 - European journal of cancer (1990)
Vulsteke Christof, Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy, p. 114157 2024 - INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
Vergote Ignace, ENGOT-EN20/GOG-3083/XPORT-EC-042-A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationa 2024 - Cancer research (Chicago, Ill.)
Krishnan Venkatesh, Abstract 5179: Tumor microenvironment (TME) biomarkers of TIGIT and PD-L1 immune checkpoint blockade in cervical cancer: An exploratory biomarker analysis from SKYSCRAPER-04 (SKY04) study
84:6_Supplement, p. 5179 - 5179 2024 - International journal of gynecological cancer
Vulsteke Christof, 556 Tolerability of the niraparib individualised starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy
34:Suppl 1, p. A580 - A581 2024 - International journal of gynecological cancer
Lorusso Domenica, 176 Rucaparib maintenance treatment in patients (Pts) with newly diagnosed ovarian cancer (OC): defining benefit according to disease risk subgroups within the phase 3 ATHENA-MONO study
34:Suppl 1, p. A298 - A299 2024 - International journal of gynecological cancer
Vergote Ignace, 1350 Tumor treating fields (TTFields) therapy in platinum-resistant ovarian cancer: results from the ENGOT-ov50/GOG-3029/INNOVATE-3 phase 3 study
34:Suppl 1, p. A576 - A576 2024 - Journal of clinical oncology
Monk Bradley J, Reply to P.-H. Luo et al, p. JCO2400077 2024 - Clinical cancer research
Eskander Ramez N., Abstract A016: NXP800, a novel, small molecule GCN2 kinase activator, demonstrates potent single-agent activity in ARID1A and ARID1B-deficient endometrial cancer xenograft models
30:5_Supplement, p. A016 - A016 2024 - Journal of gynecologic oncology
Olawaiye Alexander B., Clinical Trial Protocol for ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer
35 2024 - Kliničeskij razbor v obŝej medicine (Online)
Colombo Nicoletta, Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab (Interpretation In Rus
4:12, p. 62 - 75 2023 - CURRENT PROBLEMS IN CANCER
Bogani Giorgio, Selinexor in patients with advanced and recurrent endometrial cancer
47:6 2023 - International journal of gynecological cancer
Vergote Ignace, TP010/#397 ENGOT-EN20/GOG-3083/XPORT-EC-042 a phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma
33:Suppl 4, p. A250 - A250 2023 - Frontiers in oncology
Eskander Ramez N., Overcoming the challenges of drug development in platinum-resistant ovarian cancer
13 2023 - International journal of gynecological cancer
Bogani Giorgio, Gestational choriocarcinoma
33:10, p. ijgc-2023-004704 - 1514 2023 - International journal of gynecological cancer
Vergote Ignace, 265 ENGOT-EN20/GOG-3083/XPORT-EC-042 a phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma
33:Suppl 3, p. A414 - A415 2023 - International journal of gynecological cancer
Sehouli Jalid, 487 ARTISTRY-7: a phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68)
33:Suppl 3, p. A416 - A416 2023 - International journal of gynecological cancer
Grisham Rachel, Low-grade serous ovarian cancer: expert consensus report on the state of the science, p. ijgc-2023-004610 2023 - Journal of clinical oncology
Slomovitz Brian M., Long-term follow up of selinexor maintenance in patients with TP53 wt advanced or recurrent endometrial cancer: A pre-specified subgroup analysis from the phase 3 ENGOT-EN5/GOG-3055/SIENDO study
41:36_suppl, p. 427956 - 427956 2023 - INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
Santin Alessandro D, Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
33:4, p. 562 - 570 2023 - Cancers
Nemunaitis John, Clonal Neoantigen: Emerging “Mechanism-based” Biomarker of Immunotherapy Response
15:23, p. 5616 2023 - International journal of gynecological cancer
Bogani Giorgio, Endometrial carcinosarcoma
33:2, p. 147 - 174 2022 - International journal of gynecological cancer
Herzog Thomas, TP025/#1399 Artistry-7: phase 3 multicenter study of nemvaleukin alfa plus pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
32:Suppl 3, p. A235 - A235 2022 - Journal of clinical oncology
You Benoit, Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
40:34, p. 3965 - 3974 2022 - Vergote Ignace, POTENTIAL MECHANISM FOR OCULAR ADVERSE EVENTS OBSERVED WITH TISOTUMAB VEDOTIN 2022
- International journal of gynecological cancer
Colombo Nicoletta, 2022-RA-657-ESGO ENGOT-ov65/KEYNOTE-B96: phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer
32:Suppl 2, p. A251 - A251 2022 - Gynecologic oncology
Alholm Zachary, Real-world treatment drop-off among recurrent or metastatic cervical cancer patients: A US community oncology-based analysis
166:3, p. 567 - 575 2022 - Communications medicine
Rocconi Rodney P, ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
2:1, p. 106 2022 - Gynecologic oncology
Monk Bradley, Optimizing the dose of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC): A posthoc analysis of a phase 1b expansion study in ovarian cancer (319)
166, p. S166 2022 - Gynecologic oncology
Richardson Debra, UPLIFT (ENGOT-ov67/GOG-3048) a pivotal cohort of upifitamab rilsodotin (XMT-1536; UpRi), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC) in platinum-resistant ovarian cancer (585)
166, p. S284 2022 - Gynecologic oncology
Herzog Thomas, ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa, a novel engineered cytokine, in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (326)
166, p. S169 2022 - Gynecologic oncology
Smith Gabriella, Sequential targeted therapy in advanced metastatic and recurrent cervical cancer: Cost analysis of the patient journey (323)
166, p. S168 2022 - Journal of clinical oncology
Colombo Nicoletta, ENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer
40:16_suppl, p. TPS5617 - TPS5617 2022 - Gynecologic oncology
Kim Stella K., Mitigation and management strategies for ocular events associated with tisotumab vedotin
165:2, p. 385 - 392 2022 - International journal of gynecological cancer
Monk Bradley J, ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian c
31:12, p. 1589 - 1594 2021 - The cancer journal (Sudbury, Mass.)
Smith Gabriella, DNA Damage Repair Inhibitors-Combination Therapies
27:6, p. 501 - 505 2021 - Gynecologic oncology
Fuh Katherine C., Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer
163:2, p. 254 - 261 2021 - International journal of gynecological cancer
Chase D M, 961 Impact of disease progression on health-related quality of life of advanced ovarian cancer (AOC) patients – pooled analysis from the PRIMA trial
31:Suppl 3, p. A284 - A284 2021 - Gynecologic oncology
Herzog Thomas, A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy/safety of farletuzumab in combination with carboplatin plus paclitaxel or carboplatin plus pegylated liposomal doxorubicin (PLD) in women with low CA-125 platinum-sensit
162, p. S38 - S39 2021 - Cancer medicine (Malden, MA)
Jones Robin L, Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer
10:11, p. 3565 - 3574 2021 - Journal of clinical oncology
Vergote Ignace, Tisotumab vedotin versus investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT-cx12/GOG 3057, trial in progress)
39:15_suppl, p. TPS5596 - TPS5596 2021 - International journal of gynecological cancer
Slomovitz Brian, Asbestos and ovarian cancer: examining the historical evidence
31:1, p. 122 - 128 2021 - Gynecologic oncology
Chan John K., Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance
159:3, p. 604 - 606 2020 - Clinical advances in hematology & oncology
Moore Kathleen N., PARP Inhibition in Recurrent Ovarian Cancer
18:10, p. 647 - 655 2020 - Clinical advances in hematology & oncology
Moore Kathleen N., PARP Inhibition as Frontline Therapy in Ovarian Cancer
18:9, p. 550 - 556 2020 - Journal of clinical oncology
Madhavan Subha, A cloud-based virtual tumor board to facilitate treatment recommendations for patients with advanced cancers
36:15_suppl, p. 6508 - 6508 2018 - Gynecologic oncology
Barnes Dominique, Clinic-based Depression Screening in Gynecologic Oncology Patients using the Patient Health Questionnaires-2 (PHQ-2): are we identifying the highest risk patients?
147:1, p. 215 - 215 2017 - Journal of clinical oncology
Chan John K, Reply to F.M. Muggia
34:8, p. 882 - 883 2016 - Journal of clinical oncology
Herzog Thomas J, In assessing surrogate clinical trial end points: drug safety is a requisite
33:13, p. 1511 - 1512 2015 - Journal of clinical oncology
Monk Bradley J., The MEK Inhibitor in Low-Grade Serous Ovarian Cancer (MILO)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous ca
32:15_suppl, p. TPS5618 - TPS5618 2014